Recombinant Human IL2 Protein, C-His: A Powerful Therapeutic Target in Cancer Treatment
Interleukin-2 (IL2) is a cytokine that plays a crucial role in the immune system by stimulating the proliferation and activation of T cells, B cells, and natural killer cells. However, the therapeutic potential of IL2 has been limited due to its short half-life and potential side effects. To overcome these challenges, scientists have developed a recombinant form of human IL2 protein, C-His, which has shown promising results in cancer treatment. In this article, we will explore the structure, activity, and application of recombinant human IL2 protein, C-His as a therapeutic target.
Structure of Recombinant Human IL2 Protein, C-His
Recombinant human IL2 protein, C-His is a genetically engineered version of the naturally occurring IL2 protein. It is produced by cloning the gene for IL2 into a bacterial or mammalian expression system, followed by purification and modification to add a C-terminal His-tag. This His-tag allows for easy purification and detection of the protein.
The recombinant IL2 protein, C-His has a similar structure to the native IL2 protein, consisting of 133 amino acids. It has a molecular weight of 15.5 kDa and forms a homodimer in solution. Each monomer contains four alpha-helices and a four-stranded antiparallel beta-sheet, which are important for its biological activity.
Activity of Recombinant Human IL2 Protein, C-His
Recombinant human IL2 protein, C-His has potent immune-stimulating activity, similar to the native IL2 protein. It binds to the IL2 receptor (IL2R) on the surface of immune cells, triggering a cascade of signaling events that result in cell proliferation, activation, and cytokine production. This leads to an increase in the number and function of T cells, B cells, and natural killer cells, which are essential for fighting against cancer cells.
One of the major advantages of recombinant human IL2 protein, C-His is its extended half-life compared to native IL2. This is due to the addition of a polyethylene glycol (PEG) moiety, which increases its stability and reduces its clearance from the body. This allows for less frequent dosing and better control of IL2 levels in the body, reducing the risk of side effects.
Application of Recombinant Human IL2 Protein, C-His
The primary application of recombinant human IL2 protein, C-His is in cancer treatment. IL2 has been shown to have potent anti-tumor activity by stimulating the immune system to attack cancer cells. However, the use of native IL2 has been limited due to its toxicity and short half-life. Recombinant human IL2 protein, C-His overcomes these limitations and has shown promising results in clinical trials for the treatment of various types of cancer, including melanoma, renal cell carcinoma, and metastatic breast cancer.
In addition to its therapeutic potential, recombinant human IL2 protein, C-His also has research use in studying the immune system and developing new immunotherapies. It can be used to stimulate immune cells in vitro and in animal models to understand their function and response to different stimuli. Its long half-life and stability make it a valuable tool for studying the effects of IL2 on the immune system.
In Conclusion
Recombinant human IL2 protein, C-His is a powerful therapeutic target in cancer treatment. Its similar structure and potent activity to native IL2 make it an ideal candidate for stimulating the immune system to fight against cancer. Its extended half-life and stability make it a safer and more effective alternative to native IL2.
There are no reviews yet.